Results 11 to 20 of about 181,344 (173)

Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis

Frontiers in Oncology, 2022
Immune checkpoint inhibitor (ICI)-induced colitis is one of the known complications of therapies targeting cytotoxic programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and programmed cell death ligand 1 (PD-L1).
Leilei Fang, Changqin Liu, Xiaomin Sun, Zhanju Liu   +3 more
doaj   +1 more source

A BRCA2 germline mutation and high expression of immune checkpoints in a TNBC patient

Cell Death Discovery, 2023
Triple-negative breast cancer (TNBC) is the most aggressive subtype of mammary carcinoma. Here, we describe a case of an 81-year-old female diagnosed with ductal triple negative breast cancer with a germline pathogenic variant in BReast CAncer gene2 ...
Yuyi Han, Valentina Rovella, Artem Smirnov, Oreste Claudio Buonomo, Alessandro Mauriello, Tommaso Perretta, Yufang Shi, Jonathan Woodmsith, Julia Bischof, TOR CENTRE, Gerry Melino, Eleonora Candi, Francesca Bernassola   +12 more
doaj   +1 more source

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]

, 2016
PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R., Bi, Wenya Linda, Du, Ziming, Dunn, Gavin P, Dunn, Ian F, Fecci, Peter E, Freeman, Gordon J, Greenwald, Noah F, Kaiser, Ursula B, Laws, Edward R, Jr, Mei, Yu, Reardon, David A, Santagata, Sandro, Woodmansee, Whitney W   +13 more
core   +21 more sources

Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?

Translational Oncology, 2020
Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results.
Cinzia Solinas, Marco Aiello, Esdy Rozali, Matteo Lambertini, Karen Willard-Gallo, Edoardo Migliori   +5 more
doaj   +1 more source

T follicular helper cells: linking cancer immunotherapy and immune-related adverse events

Journal for ImmunoTherapy of Cancer, 2021
Cancer immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of numerous cancer types. As the underlying mechanism of these treatments lies in the interference with inhibitory signals that usually impair potent ...
Dirk Baumjohann, Peter Brossart
doaj   +1 more source

Immunohistochemical Expression of Programmed Death Ligand-1 in Tumour Milieu of Oral Cancer

Annals of Abbasi Shaheed Hospital and Karachi Medical & Dental College, 2020
Objectives: To determine the immunohistochemical expression of PD-L1 in oral squamous cell carcinoma and to correlate it with clinicopathological parameters.
Moomal Aslam Khan, Serajuddaula Syed, Noor Ul Wahab, Saima Akram Butt   +3 more
doaj   +1 more source

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]

, 2020
PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P, Andtbacka, Robert HI, Arlauckas, Sean P, Ballesteros-Merino, Carmen, Bannavong, Donna, Bhatia, Shailender, Bifulco, Carlos, Browning, Erica, Canton, David A, Daud, Adil I, Fong, Lawrence, Fox, Bernard A, Francisco, Murray, Gargosky, Sharron, Garris, Christopher, Hermiz, Reneta, Le, Mai, Levine, Lauren P, Oglesby, Arielle, Pierce, Robert, Pittet, Mikael J, Rosenblum, Michael D, Tsai, Katy K, Twitty, Christopher G   +23 more
core   +2 more sources

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma

Animal Models and Experimental Medicine, 2021
Programmed cell death protein 1 (PD‐1) /programmed cell death ligand 1 (PD‐L1) blockade is an important therapeutic strategy for melanoma, despite its low clinical response.
Yuchen Wang, Zhaojun Li, Zhihui Zhang, Xiaoguang Chen   +3 more
doaj   +1 more source

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study

JTO Clinical and Research Reports, 2021
Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-ligand 2)
Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD   +10 more
doaj   +1 more source